Schizophrenia
E-learning Platform

Development timeline: 2024-2025

Education about schizophrenia is essential to effectively living with and treating the disease, but comprehensive, reliable, schizophrenia-specific education is not readily accessible or tailored for specific perspectives. To truly change the way schizophrenia is understood – and the way people with this severe brain disease are treated in our society – we must educate all of the stakeholders who determine the fate of people who live with schizophrenia.

S&PAA is creating the only freely accessible e-learning platform that will house easy-to-understand, evidence-based information in one place, incorporating best-practice learning principles to empower people with schizophrenia and their caregivers. The scalable education platform also will be adaptable for a variety of stakeholders.

Phase I development centers on education for people living with schizophrenia, their caregivers and loved ones. Phase II will focus on professional education and training in areas that most significantly affect the lives of people with schizophrenia within our current systems. This is the front line in the battle to change how schizophrenia is understood and managed – and to build support for systems change from within the system.

For more details, contact Marissa Shepherd at marissa.shepherd@sczaction.org.

More Projects

Schizophrenia
E-learning Platform

Schizophrenia
E-learning Platform

We’re creating the only freely accessible e-learning platform to empower people with schizophrenia & their caregivers to understand & manage the disease.
More Information

Cost of Schizophrenia Policy Tracker

Cost of Schizophrenia Policy Tracker

We’re building the first-known state-level online interface that will track the costs of schizophrenia for use by policymakers & advocates.
More Information

NextGen Summit

NextGen Summit

The Schizophrenia Policy & Research Institute NextGen conference will convene clinicians, researchers, families, policymakers, industry & people living with schizophrenia to drive improved treatment & access.
More Information